Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shaji Kumar

Showing results (101-110 of 515) with videos related to

Pageof 52
Sort By:
Current Opinion in Oncology|February 3, 2007
Transplantation for amyloidosisMorie A Gertz, Martha Q Lacy, Angela Dispenzieri, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 2, 2011
IgM monoclonal gammopathy of undetermined significance (MGUS) and smoldering Waldenström's macroglobulinemia (SWM)Robert A Kyle, Angela Dispenzieri, Shaji Kumar, et al.
Leukemia Research|October 17, 2013
Genetic variants in DNA repair pathways are not associated with disease progression among multiple myeloma patientsBharat Thyagarajan, Mukta Arora, Weihua Guan, et al.
The Journal of Applied Laboratory Medicine|August 24, 2020
Free Light Chain Assay Drift: Potential for Misdiagnosis?David Murray, Angela Dispenzieri, Shaji Kumar, et al.
Hematology (Amsterdam, Netherlands)|September 3, 2021
3-weekly daratumumab-lenalidomide/pomalidomide-dexamethasone is highly effective in relapsed and refractory multiple myelomaChor Sang Chim, Shaji Kumar, Vincent Kai Chung Wong, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 11, 2023
Disease Monitoring In Multiple MyelomaJens Hillengass, Tom Martin, Noemi Puig, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 21, 2024
Navigating High-Risk and Ultrahigh-Risk Multiple Myeloma: Challenges and Emerging StrategiesMatthew J Rees, Mattia D'Agostino, Lisa B Leypoldt, et al.
Blood Cancer Journal|November 15, 2023
Outcomes of t(11;14) light chain (AL) amyloidosis after autologous stem cell transplantation: benchmark for new therapiesSusan Bal, Noel Estrada-Merly, Luciano J Costa, et al.
Leukemia & Lymphoma|January 19, 2008
Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosisMorie Gertz, Martha Lacy, Angela Dispenzieri, et al.
Blood Cancer Journal|February 16, 2023
Artificial intelligence-enabled screening strategy for drug repurposing in monoclonal gammopathy of undetermined significanceAlexander J Ryu, Shaji Kumar, Angela Dispenzieri, et al.
Pageof 52

Showing results (101-110 of 515) with videos related to

Sort By:
Pageof 52
Current Opinion in Oncology|February 3, 2007
Transplantation for amyloidosisMorie A Gertz, Martha Q Lacy, Angela Dispenzieri, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 2, 2011
IgM monoclonal gammopathy of undetermined significance (MGUS) and smoldering Waldenström's macroglobulinemia (SWM)Robert A Kyle, Angela Dispenzieri, Shaji Kumar, et al.
Leukemia Research|October 17, 2013
Genetic variants in DNA repair pathways are not associated with disease progression among multiple myeloma patientsBharat Thyagarajan, Mukta Arora, Weihua Guan, et al.
The Journal of Applied Laboratory Medicine|August 24, 2020
Free Light Chain Assay Drift: Potential for Misdiagnosis?David Murray, Angela Dispenzieri, Shaji Kumar, et al.
Hematology (Amsterdam, Netherlands)|September 3, 2021
3-weekly daratumumab-lenalidomide/pomalidomide-dexamethasone is highly effective in relapsed and refractory multiple myelomaChor Sang Chim, Shaji Kumar, Vincent Kai Chung Wong, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 11, 2023
Disease Monitoring In Multiple MyelomaJens Hillengass, Tom Martin, Noemi Puig, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 21, 2024
Navigating High-Risk and Ultrahigh-Risk Multiple Myeloma: Challenges and Emerging StrategiesMatthew J Rees, Mattia D'Agostino, Lisa B Leypoldt, et al.
Blood Cancer Journal|November 15, 2023
Outcomes of t(11;14) light chain (AL) amyloidosis after autologous stem cell transplantation: benchmark for new therapiesSusan Bal, Noel Estrada-Merly, Luciano J Costa, et al.
Leukemia & Lymphoma|January 19, 2008
Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosisMorie Gertz, Martha Lacy, Angela Dispenzieri, et al.
Blood Cancer Journal|February 16, 2023
Artificial intelligence-enabled screening strategy for drug repurposing in monoclonal gammopathy of undetermined significanceAlexander J Ryu, Shaji Kumar, Angela Dispenzieri, et al.
Pageof 52